Roche Receives FDA Approval for First Companion Diagnostic to Assess PTEN Protein in Prostate Cancer

FDA Approves Roche's VENTANA PTEN Diagnostic for Prostate Cancer

Roche announced FDA approval for its VENTANA PTEN (SP218) RxDx Assay, the first immunohistochemistry companion diagnostic to identify PTEN protein loss in prostate adenocarcinoma. This approval enables clinicians to identify patients eligible for treatment with AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone acetate. PTEN loss is linked to faster disease progression and reduced benefit from standard treatments. Approximately 25% of metastatic hormone-sensitive prostate cancer patients have PTEN-deficient tumors. The assay's approval is based on the CAPItello-281 study, where TRUQAP combination therapy showed a statistically significant and clinically meaningful reduction in disease progression in PTEN-deficient patients.

• Roche's VENTANA PTEN (SP218) RxDx Assay is the first FDA-approved IHC companion diagnostic for identifying PTEN protein loss in prostate adenocarcinoma. This diagnostic is crucial for personalizing treatment, as it helps clinicians select patients who may benefit from TRUQAP (capivasertib) in combination with abiraterone acetate, addressing an unmet medical need in prostate cancer management.
• The approval is based on the CAPItello-281 study, which demonstrated that patients with PTEN-deficient tumors, identified by the assay, experienced a statistically significant and clinically meaningful reduction in disease progression when treated with TRUQAP combination therapy. This offers a new first-line treatment option for PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer, where specific targeted therapies were previously unavailable.
• PTEN protein loss is a significant biomarker in prostate cancer, associated with more aggressive disease progression and reduced efficacy of current standard-of-care treatments. The diagnostic targets this specific biological characteristic, which affects about 25% of patients with metastatic hormone-sensitive prostate cancer, highlighting its importance in guiding therapeutic decisions and potentially improving patient outcomes.

Addressing Unmet Needs in PTEN-Deficient Prostate Cancer

Treatment of PTEN-deficient metastatic prostate cancer faces significant clinical obstacles despite advances in precision medicine and pathway-targeted therapeutics. Current approaches targeting the PI3K/AKT/mTOR pathway have demonstrated limited clinical benefit due to treatment-associated toxicities, resistance mechanisms, and complex pathway interactions that enable therapeutic escape.

• Limited therapeutic efficacy of pathway inhibitors — PI3K/AKT/mTOR pathway inhibitors have shown only limited benefit in prostate cancer due to associated side effects, with patients experiencing significant toxicities including pneumonitis and hyperglycemia that limit sustained treatment

• Resistance mechanism development — Cancer cells develop resistance through feedback activation of alternative pathways, adaptive tumor responses, and treatment-emergent mutations, with crosstalk between androgen signaling and PI3K/AKT/mTOR cascades activating pro-survival signals

• Bypass of upstream pathway inhibition — LY294002 and similar PI3K inhibitors, while effective at blocking prostate cancer cell growth, act upstream of AKT and PTEN, allowing cancer cells to find alternative routes to bypass this inhibition

• Disease insensitivity to single-agent approaches — Despite frequent PTEN loss and activated Akt/mTOR signaling, prostate cancer demonstrates insensitivity to single-agent mTOR inhibition, highlighting the need for combination therapeutic strategies

• Complex molecular pathway interactions — Superactivation of the prosurvival PI3K-AKT signaling pathway limits efficacy of PARP inhibitors in PTEN-deficient settings, while reciprocal feedback loops between signaling cascades complicate targeted intervention

• Need for improved patient stratification — While PTEN loss provides a valuable biomarker for patient stratification, novel combination approaches and biomarkers predictive of patient response are urgently needed to optimize therapeutic outcomes and overcome resistance barriers

VENTANA PTEN Assay: A New Tool for Patient Identification

The identification of PTEN-deficient metastatic prostate cancer in clinical practice relies primarily on tissue-based detection methods that assess both genetic deletions and protein expression. Fluorescence in situ hybridization (FISH) serves as the gold standard for detecting PTEN deletions and mutational status, offering superior standardization despite being more labor-intensive than alternative approaches. Immunohistochemistry (IHC) provides a complementary method for detecting PTEN protein loss, with automated PTEN immunostaining on Ventana platforms demonstrating robust performance across different preanalytic conditions and institutional settings. Advanced molecular techniques including hybridization exon-capture next-generation sequencing-based assays enable comprehensive detection of PTEN alterations, while copy-number alteration analysis of formalin-fixed paraffin-embedded specimens allows for detailed genomic characterization.

PTEN deficiency demonstrates distinct molecular characteristics that inform patient identification strategies. Deletions occur in approximately 20% of prostate cancers, with 8.1% showing heterozygous deletions and 12.1% homozygous deletions. These alterations strongly correlate with advanced tumor stage, high Gleason grade, lymph node metastasis, and hormone-refractory disease. Biallelic PTEN inactivation typically occurs through either homozygous deletion or deletion of one allele combined with mutation of the other, characterizing particularly aggressive subsets of metastatic and hormone-refractory prostate cancers. In metastatic hormone-sensitive prostate cancer, PTEN-low expression occurs in 28.2% of patients and associates with shorter castration-resistant progression-free survival and overall survival.

The clinical utility of PTEN assessment extends beyond simple detection to prognostic stratification and treatment guidance. PTEN loss independently predicts biochemical recurrence and associates with nonorgan confined disease at prostatectomy, with hazard ratios reaching 2.46 in biopsy specimens. In castration-resistant prostate cancer patients receiving abiraterone, PTEN protein loss occurs in 40% of cases and correlates with shorter median overall survival (14 vs 21 months) and reduced treatment duration. The integration of PTEN status with other molecular markers, including AR-V7, TP53, and ERBB2, enables identification of distinct biological subtypes with specific therapeutic implications, supporting the incorporation of PTEN assessment into routine clinical practice for treatment personalization and risk stratification.

Reshaping the Treatment Landscape for mAPMN/S Prostate Cancer

Current standard of care for metastatic hormone-sensitive prostate cancer (mHSPC) includes docetaxel, abiraterone acetate, apalutamide, enzalutamide, and radiotherapy to the primary tumor, all of which have demonstrated significant survival prolongation benefits. These treatments represent the established therapeutic backbone for patients with androgen pathway modulation-naïve or sensitive metastatic prostate cancer, regardless of PTEN status. However, PTEN deficiency, which occurs in approximately 40% of prostate cancer patients, presents unique clinical considerations as preclinical evidence suggests that PI3K/AKT pathway activation through PTEN loss can confer resistance to hormonal therapies.

The recognition of PTEN loss as a valuable biomarker for patient stratification has prompted investigation into targeted therapeutic approaches specifically designed for PTEN-deficient tumors. Recent phase II and III clinical trials have shown promising outcomes with AKT inhibitors ipatasertib and capivasertib when combined with androgen deprivation therapies in patients with metastatic castration-resistant prostate cancer and PTEN loss. Additionally, several ongoing trials are currently evaluating various AKT inhibitors in different combinations across multiple disease stages, reflecting the growing emphasis on precision medicine approaches in this patient population.

Emerging therapeutic strategies for PTEN-deficient prostate cancer extend beyond traditional PI3K-AKT-mTOR pathway inhibition to include novel approaches aimed at restoring PTEN function and targeting PTEN's regulatory roles in chromosome stability, DNA damage repair, and tumor microenvironment modulation. While these investigational approaches show promise, the optimal treatment sequencing and integration of PTEN status as a predictive biomarker in clinical decision-making remains an active area of research, with targeting PTEN-deficient prostate cancer continuing to present significant clinical challenges.

Capivasertib and PTEN CDx: Reshaping mHSPC Treatment

The recent FDA approval of the VENTANA PTEN (SP218) RxDx Assay, alongside AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone acetate, marks a pivotal moment for patients battling metastatic hormone-sensitive prostate cancer (mHSPC). This development ushers in a new era of precision medicine for a subset of prostate cancer patients whose disease is driven by a specific molecular alteration: PTEN protein loss.

PTEN deficiency is not merely a genetic anomaly; it's a critical driver of prostate cancer progression. Research indicates that the inactivation of PTEN leads to the activation of the PI3K-AKT pathway, a central signaling cascade that promotes cell growth and survival. This activation is linked to poorer clinical outcomes and can reduce the effectiveness of standard treatments. With approximately 25% of mHSPC patients exhibiting PTEN-deficient tumors, identifying these individuals is paramount.

The newly approved companion diagnostic assay provides a crucial tool for clinicians, allowing them to accurately pinpoint patients who are most likely to respond to capivasertib. Capivasertib, a pan-AKT inhibitor, works by blocking this activated pathway, and when combined with abiraterone acetate, it has demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival in PTEN-deficient mHSPC patients, as evidenced by the CAPItello-281 study.

However, this targeted approach comes with considerations. While the combination offers a new therapeutic avenue, the safety profile indicates a notable increase in adverse events such as diarrhea, hyperglycemia, and rash, which will require careful management to maintain patient quality of life and treatment adherence. Furthermore, while promising in this specific mHSPC setting, studies in broader or later-line metastatic castration-resistant prostate cancer populations have shown less consistent benefits, underscoring the importance of precise patient selection based on PTEN status. The diagnostic's ability to accurately define PTEN deficiency, potentially with increasingly stringent cut-offs, will be key to realizing the full clinical potential of this combination therapy. This approval reinforces the growing trend towards biomarker-driven strategies, offering hope for more personalized and effective treatments in oncology.